Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole- intolerant, HIV-infected individuals

U. P. Jorde, H. W. Horowitz, G. P. Wormser

Research output: Contribution to journalArticle

49 Scopus citations


Objective: To determine the safety and efficacy of 100 mg dapsone three times weekly for Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV-infected, trimethoprim-sulfamethoxazole (TMP-SMX)-intolerant patients. Design: Retrospective chart review of patients followed-up to 22 May 1992. Setting: Infectious diseases outpatient clinic of a tertiary care center in suburban New York City. Patients: Twenty-three HIV-infected patients requiring PCP prophylaxis with documented intolerance to TMP-SMX. Main outcome measures: Patients were followed clinically and with laboratory testing at approximately monthly intervals. Results: Dapsone was discontinued in nine (39%) patients because of adverse reactions. All reactions occurred within the first 2 months of treatment. Two (14%) of the remaining 14 patients developed histologically proven PCP over 126 patient-months of follow-up. Conclusion: Approximately 40% of TMP-SMX-intolerant HIV-infected individuals are also intolerant of dapsone. Prophylaxis failures may be expected on a dose regimen of 100 mg dapsone three times weekly. More experience with other dose regimens and alternative agents is needed.

Original languageEnglish (US)
Pages (from-to)355-359
Number of pages5
Issue number3
Publication statusPublished - Apr 23 1993
Externally publishedYes



  • Cross-reactivity
  • Dapsone
  • HIV
  • Intolerance
  • Pneumocystis carinii
  • Trimethoprim-sulfamethoxazole

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this